NASDAQ:PYXS Pyxis Oncology (PYXS) Stock Price, News & Analysis $1.23 +0.03 (+2.50%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.20 -0.02 (-2.03%) As of 05/23/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Pyxis Oncology Stock (NASDAQ:PYXS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Pyxis Oncology alerts:Sign Up Key Stats Today's Range$1.16▼$1.2550-Day Range$0.88▼$1.2652-Week Range$0.83▼$5.39Volume471,961 shsAverage Volume739,771 shsMarket Capitalization$76.20 millionP/E RatioN/ADividend YieldN/APrice Target$9.00Consensus RatingModerate Buy Company OverviewPyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.Read More… Pyxis Oncology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks31st Percentile Overall ScorePYXS MarketRank™: Pyxis Oncology scored higher than 31% of companies evaluated by MarketBeat, and ranked 771st out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingPyxis Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoveragePyxis Oncology has only been the subject of 2 research reports in the past 90 days.Read more about Pyxis Oncology's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Pyxis Oncology are expected to decrease in the coming year, from ($1.04) to ($1.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pyxis Oncology is -1.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pyxis Oncology is -1.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPyxis Oncology has a P/B Ratio of 0.44. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted16.42% of the float of Pyxis Oncology has been sold short.Short Interest Ratio / Days to CoverPyxis Oncology has a short interest ratio ("days to cover") of 12.3, which indicates bearish sentiment.Change versus previous monthShort interest in Pyxis Oncology has recently increased by 1.40%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPyxis Oncology does not currently pay a dividend.Dividend GrowthPyxis Oncology does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted16.42% of the float of Pyxis Oncology has been sold short.Short Interest Ratio / Days to CoverPyxis Oncology has a short interest ratio ("days to cover") of 12.3, which indicates bearish sentiment.Change versus previous monthShort interest in Pyxis Oncology has recently increased by 1.40%, indicating that investor sentiment is decreasing. News and Social Media3.2 / 5News Sentiment0.69 News SentimentPyxis Oncology has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Pyxis Oncology this week, compared to 2 articles on an average week.Search Interest1 people have searched for PYXS on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Pyxis Oncology to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Pyxis Oncology insiders have not sold or bought any company stock.Percentage Held by Insiders10.60% of the stock of Pyxis Oncology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 39.09% of the stock of Pyxis Oncology is held by institutions.Read more about Pyxis Oncology's insider trading history. Receive PYXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pyxis Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address PYXS Stock News HeadlinesAnalysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS), Globus Medical (GMED) and Ramsay Health Care (OtherRMSYF)May 22 at 3:31 AM | theglobeandmail.comQ2 EPS Estimates for Pyxis Oncology Cut by HC WainwrightMay 22 at 1:21 AM | americanbankingnews.comMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millions of years. And both grizzled oilmen and clean energy supporters love it: Energy Secretary Chris Wright called it "an awesome resource," while Warren Buffett, Jeff Bezos, Mark Zuckerberg, and Bill Gates are all directly invested.May 24, 2025 | Stansberry Research (Ad)HC Wainwright Comments on Pyxis Oncology Q1 EarningsMay 21 at 4:05 AM | americanbankingnews.comPyxis Oncology's (PYXS) Buy Rating Reiterated at HC WainwrightMay 20, 2025 | americanbankingnews.comPyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 15, 2025 | globenewswire.comPyxis Oncology to Participate in Two Upcoming Investor ConferencesMay 14, 2025 | globenewswire.comNew Approaches to Tumor Targeting Are Driving the Next Wave of Oncology BreakthroughsMay 8, 2025 | baystreet.caSee More Headlines PYXS Stock Analysis - Frequently Asked Questions How have PYXS shares performed this year? Pyxis Oncology's stock was trading at $1.56 at the start of the year. Since then, PYXS shares have decreased by 21.2% and is now trading at $1.23. View the best growth stocks for 2025 here. How were Pyxis Oncology's earnings last quarter? Pyxis Oncology, Inc. (NASDAQ:PYXS) posted its quarterly earnings results on Thursday, May, 15th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.29) by $0.06. When did Pyxis Oncology IPO? Pyxis Oncology (PYXS) raised $158 million in an initial public offering (IPO) on Friday, October 8th 2021. The company issued 10,500,000 shares at a price of $14.00-$16.00 per share. Who are Pyxis Oncology's major shareholders? Pyxis Oncology's top institutional investors include 683 Capital Management LLC (0.89%), Pier 88 Investment Partners LLC (0.63%), Goldman Sachs Group Inc. (0.26%) and Nuveen LLC (0.21%). Insiders that own company stock include Pfizer Inc, Lara Sullivan, Pamela Ann Connealy and Jitendra Wadhane. View institutional ownership trends. How do I buy shares of Pyxis Oncology? Shares of PYXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Pyxis Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pyxis Oncology investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Walmart (WMT), Home Depot (HD) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings5/15/2025Today5/24/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PYXS CIK1782223 Webwww.pyxisoncology.com Phone617-221-9059FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Stock Price Target$9.00 High Stock Price Target$13.00 Low Stock Price Target$5.00 Potential Upside/Downside+631.7%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-73,790,000.00 Net MarginsN/A Pretax Margin-355.24% Return on Equity-36.22% Return on Assets-28.76% Debt Debt-to-Equity RatioN/A Current Ratio7.33 Quick Ratio7.33 Sales & Book Value Annual Sales$16.15 million Price / Sales4.72 Cash FlowN/A Price / Cash FlowN/A Book Value$2.81 per share Price / Book0.44Miscellaneous Outstanding Shares61,948,000Free Float53,638,000Market Cap$76.20 million OptionableOptionable Beta1.15 Free Today: Your Guide to Smarter Options TradesLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:PYXS) was last updated on 5/24/2025 by MarketBeat.com Staff From Our PartnersBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | Sponsored$19 for a FULL YEAR of stock picks?!Invest in Musk's AI Play With Just $100 You don't need deep pockets to ride the next wave of AI wealth. ...Behind the Markets | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredBig Oil’s big pivotThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredAfter Monday, price goes up 600% (hurry)Right now, for a limited time… You can get up to 52 Money Monday trades for just $7! Thanks to Wall Street’...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pyxis Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pyxis Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.